Clinical Report: Impact of Regular Plasmapheresis on Severe Renal Impairment

Overview

This case study highlights the successful use of regular plasmapheresis in a critically ill patient with severe renal impairment due to anti-GBM disease. The patient's renal function was restored and maintained normal over a 5-year follow-up period, suggesting the potential benefit of persistent plasmapheresis in similar cases.

Background

Anti-glomerular basement membrane (anti-GBM) disease is a rare autoimmune disorder that can lead to rapid kidney failure and has a poor prognosis, particularly in severe cases. Standard treatments include plasmapheresis, immunosuppressive therapy, and corticosteroids, but their efficacy in critically ill patients remains uncertain. Understanding effective treatment strategies is crucial for improving outcomes in this high-risk population.

Data Highlights

The patient underwent 25 rounds of plasmapheresis, leading to a significant recovery in renal function, which was sustained during a 5-year follow-up.

Key Findings

• The patient presented with severe renal impairment (creatinine 752 μmol/L) and anti-GBM antibodies.
• Persistent plasmapheresis was performed until pathogenic autoantibodies were cleared.
• Renal function was successfully restored and remained normal over a 5-year follow-up.
• Early initiation of plasmapheresis combined with immunosuppressive therapy may improve outcomes in severe anti-GBM disease.
• Standard treatment protocols may not be effective for patients with severe disease at presentation.

Clinical Implications

Clinicians should consider early and persistent plasmapheresis in patients with severe anti-GBM disease to potentially improve renal outcomes. This case underscores the importance of individualized treatment strategies in critically ill patients with autoimmune kidney disorders.

Conclusion

The successful recovery of renal function in this case suggests that aggressive treatment with plasmapheresis may offer hope for patients with severe anti-GBM disease. Further studies are needed to validate these findings and refine treatment protocols.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Rituximab is Associated with Accelerated Dialysis Independence in Anti-glomerular Basement Membrane Disease: A Retrospective Cohort Analysis of Renal Survival
2. Frontiers in Immunology, 2026 -- Case Report: Anti-glomerular basement membrane disease during pregnancy with favorable renal outcome, sequential biopsies, and dual anti-α1/α3(IV) and anti-LM521 antibodies
3. Clinical Rheumatology, 2025 -- Recurrent Spontaneous Renal Bleeding in Patients with End-Stage Renal Disease and ANCA-Associated Vasculitis: A Review of Case Studies
4. Intensive Care Medicine — Inactivation of Circulating Proapoptotic Factors via Polymyxin-B Hemoperfusion
5. Complement in anti-glomerular basement membrane glomerulonephritis
6. Double-filtration plasmapheresis versus therapeutic plasma exchange in the treatment of anti-glomerular basement membrane nephritis: A cohort study
7. Hansa ger uppdatering om den registreringsgrundande fas 3-studien för anti-glomerulär basalmembransjukdom (anti-GBM) - Hansa Biopharma AB